Getting TRT online: what the hype glosses over

What did @kmartfit actually say?

The creator walks viewers through a referral-based funnel for online TRT access. The pitch is simple: comment the word 'TRT,' get a link, fill out a form, hop on a free 15-minute call with a patient care coordinator, get bloodwork at Quest Diagnostics using a discount code, have a doctor review it, and receive testosterone cypionate shipped to your door for 'under $200 a month.' That price is said to include telemedicine visits and quarterly bloodwork.

To be clear about what this video actually is: it is an affiliate or referral promotion. The creator says 'the clinic I work with' twice, which signals a compensated relationship. That doesn't automatically make the information wrong, but viewers deserve to know they're watching a sales funnel dressed as a how-to guide.

Does the science back this up?

The general process described, blood testing before prescribing, physician review, and follow-up labs, is medically sound and reflects standard-of-care guidelines. The American Urological Association and the Endocrine Society both require documented low testosterone via serum testing before initiating TRT. So the bones of this process are legitimate.

Where it gets murkier is the framing. Legitimate hypogonadism is defined as total testosterone below roughly 300 ng/dL with accompanying symptoms, per Bhasin et al., 2010, Journal of Clinical Endocrinology and Metabolism. Many direct-to-consumer telehealth TRT clinics, however, have been criticized for prescribing to men who fall in low-normal ranges without confirming true clinical hypogonadism. A 2023 analysis in JAMA Internal Medicine flagged that telehealth testosterone prescribing grew sharply post-pandemic, with limited evidence that all patients receiving prescriptions met guideline criteria. A 15-minute call with a patient care coordinator, not a physician, is not a clinical intake. That distinction matters.

What did they get wrong (or right)?

Credit where it's due: recommending bloodwork before starting TRT is correct. The Quest Diagnostics step is a real, functional process that many telehealth clinics use. Quarterly monitoring bloodwork is also consistent with clinical guidelines, which recommend checking hematocrit, testosterone levels, and PSA at follow-up intervals. Getting that included in a monthly fee is genuinely useful information.

What the creator got wrong, or at minimum glossed over, is significant. First, the 'free 15-minute call with a patient care coordinator' is not a medical consultation. Coordinators are not licensed clinicians. The actual physician review happens after bloodwork, which means the clinical gatekeeping is thin at the front end. Second, there is no mention of contraindications: men with polycythemia, prostate cancer history, untreated sleep apnea, or active fertility goals should not be on TRT without careful specialist input. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and causes infertility in most men within months, per Trussell et al., referenced in multiple andrology reviews. None of that is mentioned. Third, 'under $200 a month' is presented as a flat fact with no acknowledgment that pricing varies by dose, formulation, or state regulations.

What should you actually know?

Online TRT access has genuinely improved care for men who were previously underserved by traditional primary care. That is a real benefit. But the model the creator describes, comment-to-link affiliate funnels with minimal front-end clinical screening, carries real risks that a 60-second video cannot responsibly address.

Any legitimate TRT protocol should include: two separate morning testosterone measurements on different days (Endocrine Society guidelines), LH and FSH testing to distinguish primary from secondary hypogonadism, hematocrit and PSA baseline, and a discussion of fertility implications. If a clinic skips these steps because it slows the funnel, that is a red flag. The FDA has also issued warnings about testosterone therapy increasing cardiovascular risk in certain populations, particularly men over 65 with pre-existing cardiac conditions, a finding from the TRAVERSE trial published in the New England Journal of Medicine in 2023, which showed non-inferiority but did flag elevated atrial fibrillation rates. A 15-minute coordinator call will not surface any of that.

Bottom line: is this responsible health information?

The logistics described are real. The process exists and functions. But packaging a referral link promotion as a neutral how-to guide, without disclosing the affiliate relationship or mentioning a single contraindication, is a failure of responsible health content. The creator is not a clinician. The clip has 14,000 views. At minimum, anyone watching should understand they are being directed into a commercial funnel, not receiving independent medical guidance.